Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Regulatory News (N4P)

  • There is currently no data for N4P

Investment

22 Mar 2016 16:14

RNS Number : 9481S
Onzima Ventures PLC
22 March 2016
 

22 March 2016

 

Onzima Ventures PLC

 

("Onzima" or the "Company")

 

Investment

 

The Company announces that it has participated in the placing of new ordinary shares by Jubilee Platinum plc ("Jubilee") as announced today as part of a total fundraise of £2.5 million gross.

 

Jubilee has also today announced the successful completion of debt project funding for the execution and commissioning of both of its two surface platinum processing projects at Dilokong and Hernic in South Africa. The debt funding comprises a combination of senior secured debt to a maximum of USD 10 million (ZAR 153 million) and unsecured debt to a maximum of USD 5 million (ZAR 76.5 million). The total funding allows Jubilee to execute simultaneously its two projects targeting the processing of 80,000 tonnes per month of surface material, while still being able to pursue the acquisition or securing of further surface or shallow platinum bearing opportunities.

 

Onzima subscribed for 4.7million shares at 2.8p per share for a total sum of approximately £132,000.

 

Luke Cairns, Director of Onzima, stated: "We are pleased to have taken part in this fundraising at what we consider is an attractive price. Jubilee is at a transformational stage as it looks to move into production at both of its new platinum tailings operations, while its Tjate mine project progresses in the background. Jubilee expects both Dilokong and Hernic to be producing this year thus we anticipate plenty of positive newsflow in the short term."

 

 

For further information please contact:

 

Onzima Ventures PLC Tel: +44 (0) 1732 366561

Gavin Burnell, Luke Cairns

 

Nominated Adviser

Cairn Financial Advisers LLP Tel: +44 (0) 20 7148 7900

Sandy Jamieson, Liam Murray

 

Broker

Peterhouse Corporate Finance Limited Tel: +44 (0) 20 7469 0930

Guy Miller, Lucy Williams

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAKDAAFDKEFF
Date   Source Headline
17th Mar 202612:14 pmRNSResult of General Meeting and Change of Name
27th Feb 20267:00 amRNSNotice of GM and Proposed Change of Name
24th Feb 20267:00 amRNSCEO Appointment & Name Change Thalia Therapeutics
17th Dec 20257:00 amRNSBusiness and Operational Update
25th Sep 20257:00 amRNSInterim Results
23rd Sep 20257:00 amRNSPartnership with University of Strathclyde’s CMAC
22nd Sep 20257:00 amRNSN4 Pharma’s Nuvec® Targets Lung Cancer Cells
19th Sep 20257:00 amRNSNotice of Results, Analyst & Investor Presentation
11th Sep 20257:00 amRNS-RInvestor Event and Presentation
30th Jul 20251:55 pmRNS-RArticle on Nuvec®’s Potential in RNA Therapeutics
14th Jul 20257:00 amRNS-RInvestor Webinar
8th Jul 20257:00 amRNSDirectorate Change
30th Jun 20252:15 pmRNSResult of AGM
30th Jun 20257:00 amRNSAGM Statement
25th Jun 20257:00 amRNS-RInsight Event for Retail Investors
6th Jun 20257:00 amRNSFinal Results, Annual Report and Notice of AGM
27th May 20257:00 amRNS-REstablishment of New Senior Leadership Team
23rd May 202512:37 pmRNSTR-1: Notification of major holdings
21st May 20254:11 pmRNSHolding(s) in Company
15th May 20253:13 pmRNSChange of Registered Address
12th May 20257:00 amRNSN4 101 In Vivo Study Results
9th May 20258:24 amRNSHolding(s) in Company
29th Apr 20254:25 pmRNSHolding(s) in Company
29th Apr 202511:05 amRNSHolding(s) in Company
28th Apr 20252:30 pmRNSHolding(s) in Company
23rd Apr 20252:32 pmRNSTR-1: Standard form notification of major holdings
22nd Apr 202511:56 amRNSResult of General Meeting
4th Apr 20257:08 amRNSPosting of Circular and Notice of General Meeting
1st Apr 20254:08 pmRNSPlacing and Subscription to raise £1,750,000
18th Feb 202512:34 pmRNSHolding(s) in Company
7th Feb 20257:00 amRNS-RInvestor Webinar
27th Jan 20257:00 amRNS-RInvestor Webinar
16th Jan 20257:00 amRNS-RN4 Pharma Non-Executive Director Q&A
8th Jan 20257:00 amRNSDirectorate Changes
12th Dec 20247:00 amRNSN4 101 In Vitro Results
4th Dec 20247:00 amRNSNew Patent Filing
28th Nov 20247:00 amRNSGrant of Options
24th Sep 20247:00 amRNSInterim Results
17th Sep 20248:04 amRNSSRI Research Update
9th Sep 20247:00 amRNSDirector Appointment
23rd Aug 20248:30 amRNSChange of Auditor
20th Aug 20247:00 amRNSSRI Research Update
3rd Jul 20247:00 amRNSNanogenics Update
28th Jun 20247:00 amRNSTotal Voting Rights
19th Jun 20247:00 amRNSHolding(s) in Company
18th Jun 202412:34 pmRNSHolding(s) in Company
13th Jun 20244:52 pmRNSHolding(s) in Company
11th Jun 202411:16 amRNSNew Corporate Presentation
7th Jun 202410:18 amRNSPlacing and Subscription to raise £630,000
23rd May 20244:09 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.